Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. The company has licensed the North American rights to Firdapse?, a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. for the treatment of patients with Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndromes and Myasthenia Gravis. In addition, the company has launched Firdapse? in the United States, selling through a field force in neurologic, central nervous system or rare disease products consisting of field personnel.

Net 1 UEPS Technologies provides financial technology, products and services. The company has developed and owns most of its payment technologies, and where possible, utilizes this technology to provide financial and services to its customers by including them into the formal financial system. The company's primary payment technology is called the Universal Electronic Payment System (UEPS), and its EMV interoperable derivative, UEPS/EMV, utilizes a form of distributed ledger technology, providing decentralized and biometrically secure smart cards that operate in real-time but both off-line and on-line. The company's financial inclusion products and services are delivered through its UEPS-based core banking system.

Odonate Therapeutics is a pharmaceutical company focused on the development of therapeutics that improve and extend the lives of patients with cancer. The company's initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. In patients with metastatic breast cancer, tesetaxel was shown to have single-agent antitumor activity in two multicenter, Phase 2 studies. The company is conducting a multinational, multicenter, randomized, Phase 3 study in patients with locally advanced or metastatic breast cancer, known as CONTESSA.

PBF Energy is a holding company. Through its subsidiaries, the company is engaged as an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the U.S. The company operates in two business segments: refining, which the company produces a variety of products at each of its refineries such as gasoline, ultra-low-sulfur diesel, heating oil, jet fuel, lubricants, petrochemicals and asphalt; and logistics, which through its PBF Logistics LP subsidiary, the company owns or leases, operates, develops and acquires crude oil and refined petroleum products terminals, pipelines, storage facilities and similar logistics assets.

Steelcase provides furniture settings, user-centered technologies and interior architectural products. The company's furniture portfolio includes panel, fence and beam-based furniture systems, storage, fixed and height-adjustable desks, benches and tables and complementary products. The company's seating products include task chairs and seating for specific vertical markets. The company's technology solutions support group collaboration by integrating furniture and technology. The company's interior architectural products include full and partial height walls and architectural pods. The company also provides services, including workplace strategy consulting, data-driven space measurement, and lease origination services.